Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 18/20 | 0.72 |
| ▸ | EZH1 | Q92800 | 4/20 | 0.72 |
| ▸ | EED | O75530 | 4/20 | 0.69 |
| ▸ | SUZ12 | Q15022 | 4/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.66 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.55 |
| ▸ | RBBP7 | Q16576 | 1/20 | 0.55 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15833760 | 0.94 | EZH2 (0.80) | EZH2EZH1EEDSUZ12HDAC6 | |
| SCHEMBL15833792 | 0.94 | EZH2 (0.80) | EZH2EZH1EEDSUZ12HDAC6 | |
| SCHEMBL15833759 | 0.94 | EZH2 (0.80) | EZH2EZH1EEDSUZ12HDAC6 | |
| SCHEMBL15833758 | 0.92 | EZH2 (0.75) | EZH2EZH1EEDSUZ12HDAC6 | |
| SCHEMBL15833833 | 0.91 | EZH2 (0.73) | EZH2EZH1EEDSUZ12HDAC6 | |
| SCHEMBL2594727 | 0.89 | EZH2 (0.88) | EZH2EZH1EEDSUZ12HDAC6 | |
| SCHEMBL14726845 | 0.89 | EZH2 (0.88) | EZH2EZH1EEDSUZ12HDAC6 | |
| SCHEMBL14726866 | 0.89 | EZH2 (0.88) | EZH2EZH1EEDSUZ12HDAC6 | |
| SCHEMBL25671307 | 0.86 | EZH2 (0.72) | EZH2EZH1EEDSUZ12HDAC6 | |
| SCHEMBL2589003 | 0.85 | EZH2 (0.78) | EZH2EZH1EEDSUZ12HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134692-A1 | 1,4-PYRIDONE BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2018-05-17 | — | — | US | disclosed |
| EP-2935264-B1 | 1,4-PYRIDONE BICYCLIC HETEROARYL COMPOUNDS | EPIZYME INC (US) | 2017-10-18 | — | — | EP | disclosed |
| US-9701666-B2 | 1,4-pyridone bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2017-07-11 | — | — | US | disclosed |
| US-9701666-B2 | 1,4-pyridone bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2017-07-11 | — | — | US | disclosed |
| US-20150344459-A1 | 1,4-PYRIDONE BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2015-12-03 | — | — | US | disclosed |
| US-20150344459-A1 | 1,4-PYRIDONE BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2015-12-03 | — | — | US | disclosed |
| WO-2014100665-A1 | 1,4-PYRIDONE BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344459-A1 | 1,4-PYRIDONE BICYCLIC HETEROARYL COMPOUNDS | CYP4B1, PDXK, CYP1B1 | EZH2 1932/4885EZH1 2656/4885EED 4045/4885 |
| US-20180134692-A1 | 1,4-PYRIDONE BICYCLIC HETEROARYL COMPOUNDS | CYP4B1, PDXK, CYP1B1 | EZH2 1932/4885EZH1 2656/4885EED 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.